A federal advisory panel spent two days saying yes to research peptides its own agency warned against. On the last vote, it finally said no.
The FDA's Pharmacy Compounding Advisory Committee closed its two-day peptide session at the agency's White Oak campus on Friday. It recommended Semax ↗, a Russian-developed nootropic, for compounding by an 8-to-5 vote, and Epitalon ↗, a four-amino-acid peptide marketed for anti-aging, by 7 to 4, according to the regulatory trade publication RAPS ↗ and STAT News ↗. Then it reached Emideltide ↗, better known as delta sleep-inducing peptide or DSIP, and voted it down 6 to 7. It was the only rejection of the two days.
What a yes and a no mean here
The panel does not approve drugs. It advises the FDA on which bulk ingredients compounding pharmacies may legally keep on the shelf under Section 503A, the law that lets a licensed pharmacy mix a drug to order for an individual patient. A spot on that list is what would move these peptides out of the gray market, where they are already sold for "recovery" and "longevity," and into pharmacies with a prescription behind them.
Combined with Thursday's session, the panel cleared four peptides on day one ↗, including two with no human trials at all ↗. That brings the two-day tally to six of seven peptides recommended for the list. Emideltide is the one that did not make it.
Why the seventh was different
Emideltide was nominated for insomnia, narcotic dependence, and opioid withdrawal. That last indication is what appears to have split the room. Recommending a poorly characterized peptide for tissue repair is one thing. Recommending one that patients might reach for while coming off opioids raised a different order of risk.
David Pope, a pharmacy executive who had backed the earlier peptides, switched to a no on Emideltide, citing what he called "potentially dangerous downstream consequences." The FDA's own reviewers had recommended against all three of Friday's peptides, arguing the evidence for effectiveness was thin. Mary Thanh Hai, who directs the FDA's Office of New Drugs, made the underlying problem plain. "In the grey market, that's not a requirement to be sent to us," she told the panel, meaning no one has to prove these peptides work before selling them.
That is the tension the whole meeting ran on. The committee was asked to weigh ingredients for which the usual safety and efficacy record mostly does not exist. Asare Christian, a physician on the panel, said his read was "through the lens of the patient in front of me," not a dossier of trial data that was never filed.
The pattern behind the votes
Every one of the six wins overrode the FDA's career scientists, who had recommended against adding any of the seven peptides. The panel that outvoted them was assembled under Health and Human Services Secretary Robert F. Kennedy Jr., and most of the members who voted yes have ties to the peptide industry. On the seventh vote, that same panel landed where the agency staff already were.
None of this is settled. A recommendation is not a rule. Before any of the six peptides can be compounded legally, the FDA has to publish a proposed rule, open a public comment period, and issue a final rule, a process that usually takes 6 to 18 months. The administration could also overrule its own career staff along the way.
For now, the map is clearer than it was a week ago. Semax and Epitalon join BPC-157, KPV, TB-500, and MOTS-c on the recommended side. Emideltide sits alone on the other, a sleep peptide first pulled from rabbit brain in 1974, stopped at the last gate of a meeting that waved almost everything else through.